Aromatase inhibitors (AIs: letrozole, anastrozole, and lexemestane) are the recommended endocrine therapy for most post-menopausal women with estrogen receptor positive (ER+) breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.